Nova Thin Film Pharmaceuticals

What Nova Thin Film Pharmaceuticals does

Nova Thin Film Pharmaceuticals (NTFP) is a privately held specialty drug delivery company that develops and manufactures dissolving oral soluble films (OSF) using its patented DepoFilm™ platform. The company was formed as a North Carolina LLC in October 2019, with patent origins dating to April 2017, and operates from formulation laboratories in Greensboro, NC and cGMP manufacturing space leased from Quality Chemical Laboratories (QCL) in Wilmington, NC. The company employs 1-10 people.

DepoFilm™ is a thin film drug delivery technology that uses a film deposition methodology rather than conventional solution casting, enabling novel functional shapes, multi-layer compositions, higher drug loading, and integration of film formation with primary consumer-ready packaging in a single manufacturing step. The company holds six issued DepoFilm™ patents (issued between 2018 and 2021) and benefits from the broader patent estate of its founders, including Joseph Fuisz (45+ US patents) and Richard C. Fuisz (130+ US patents), who are credited with creating the modern oral soluble film industry. NTFP is advancing a proprietary pipeline of five thin film drug candidates targeting conscious sedation, erectile dysfunction, neuropathic pain, short-acting hypnotic applications, and a generic candidate (NTFP-102, 104, 106, 108, 111).

NTFP operates a sales-led, relationship-driven B2B model with two revenue streams: co-development partnerships with pharmaceutical companies on proprietary products (development services, milestones, and potential licensing) and a proprietary product pipeline (intended for licensing upon regulatory approval). The company's go-to-market is concentrated through a single strategic partner, Quality Chemical Laboratories LLC, which serves simultaneously as lead investor, manufacturing host, and co-development partner. Pricing and commercial terms are not publicly disclosed, and no products are yet approved or commercially generating revenue.

Name

Nova Thin Film Pharmaceuticals

Legal name

Nova Thin Film Pharmaceuticals LLC

Website

https://novathinfilm.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Nova Thin Film Pharmaceuticals is a specialty drug delivery company developing dissolving oral thin films via its patented DepoFilm™ platform, serving pharmaceutical partners through co-development agreements and advancing a proprietary pipeline of transmucosal drug candidates.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Delivery / Oral Soluble Thin Films

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Thin film drug delivery
• Oral soluble films
• Transmucosal pharmaceutical films
• DepoFilm manufacturing technology
• Pharmaceutical co-development

Headquarters

HQ city

Greensboro

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure

Revenue model

1. Co-development Partnerships: NTFP works with pharmaceutical partners on co-development of proprietary thin film products using DepoFilm™ technology. Revenue generated through development services, milestone payments, and potential licensing arrangements with partner companies.
2. Proprietary Product Pipeline: The company is advancing a robust pipeline of its own thin film products (NTFP-102, NTFP-104, NTFP-106, NTFP-108, NTFP-111) targeting various therapeutic areas including conscious sedation, erectile dysfunction, neuropathic pain, and short-acting hypnotic applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Nova Thin Film Pharmaceuticals is a specialty drug delivery company that develops and manufactures dissolving thin films for the pharmaceutical industry using its patented DepoFilm™ technology platform. The company uses an alternative film deposition methodology (rather than conventional solution casting) to produce oral soluble films (OSF) that enable higher drug loading, novel shapes, multi-layer compositions, and integrated primary packaging. NTFP primarily generates revenue through co-development partnerships with pharmaceutical companies on proprietary thin film products and through advancement of its own proprietary pipeline of thin film drug candidates (NTFP-102, NTFP-104, NTFP-106, NTFP-108, NTFP-111).

Product overview

Nova Thin Film Pharmaceuticals offers a single unified technology platform called DepoFilm™ for developing and manufacturing dissolving thin films for drug delivery. The company's product portfolio includes its proprietary DepoFilm™ technology as the core platform, along with a pipeline of named thin film drug candidates (NTFP-106 for conscious sedation, NTFP-104 for erectile dysfunction, NTFP-111 for neuropathic pain, NTFP-108 for short-acting hypnotic, and NTFP-102 as a generic candidate). The company operates formulation laboratories in Greensboro and manufacturing in Wilmington, North Carolina, working with partners on co-development projects.

Differentiator

Problem solved

Functional benefit

Products and services

• DepoFilm™ Technology Platform Patented thin film drug delivery technology platform — a film deposition manufacturing methodology replacing conventional solution casting for oral soluble films (OSF). Enables higher drug loading, multi-layer compositions, novel functional shapes, heat-labile API tolerance, rapid formulation prototyping (buccal, sublingual and intraoral), and integration of film formation with primary consumer-ready packaging in a single process. Licensed/used by pharmaceutical partners and leveraged internally for NTFP's own drug candidate pipeline.
• NTFP-106 (conscious sedation thin film candidate) Proprietary NTFP thin film drug candidate targeting conscious sedation; developed on the DepoFilm™ platform.
• NTFP-104 (erectile dysfunction thin film candidate) Proprietary NTFP thin film drug candidate for erectile dysfunction; developed on the DepoFilm™ platform.
• NTFP-111 (neuropathic pain thin film candidate) Proprietary NTFP thin film drug candidate targeting neuropathic pain; developed on the DepoFilm™ platform.
• NTFP-108 (short-acting hypnotic thin film candidate) Proprietary NTFP thin film drug candidate for short-acting hypnotic applications; developed on the DepoFilm™ platform.
• NTFP-102 (generic thin film candidate) Proprietary NTFP thin film drug candidate positioned as a generic; developed on the DepoFilm™ platform.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Quality Chemical Laboratories LLC (QCL)coreStrategic or Co-development Partner · 1 June 2020Quality Chemical Laboratories LLC is a leading pharmaceutical CDMO and strategic partner to NTFP. QCL is a partner and lead investor in NTFP. The partnership includes comprehensive investment and development services agreement (November 12, 2019), lease for cGMP manufacturing space in Wilmington (April 1, 2021), and co-development of soluble thin film operations. NTFP leverages QCL's manufacturing capabilities and industry expertise.

Scale indicators1 record

Recent moves10 records

Expansion highlights5 records

Direct peers

• Adhex Pharma: European CDMO focused on transdermal patches and oral thin films. Closest European functional analogue to NTFP's co-development and contract manufacturing motion in thin films.
• IntelGenx Technologies Corp. Oral thin-film drug delivery developer and manufacturer with a CDMO model and own proprietary pipeline — directly comparable in business model, route of administration, and B2B partnership focus to NTFP's DepoFilm™ platform.
• LTS Lohmann Therapie-Systeme AG: Global CDMO specializing in thin-film and transdermal drug delivery systems. Closest large-scale commercial analogue to NTFP's film deposition manufacturing approach.
• ZIM Laboratories: India-based developer of oral thin-film and orally disintegrating strip products for generics and nutraceuticals; directly comparable technology focus and proprietary + co-development business model.
• BioDelivery Sciences International (BDSI): Specialty pharma built around buccal/sublingual film delivery (e.g., Bunavail). Comparable in therapeutic-area focus (pain, CNS) and reliance on thin-film technology, now operating within Collegium.
• Corium (acquired by Gurnet Point / recently ANI Pharmaceuticals): Developer of transdermal and oral film drug delivery systems with proprietary platform and CDMO services; directly comparable technology focus and partnership-driven commercialization model.

Broad incumbents

• Cynapsus Therapeutics / Sunovion (Sumitomo): Developed and commercialized apomorphine sublingual film (APL-130277 / Kynmobi). Demonstrates the prescription sublingual film commercial pathway NTFP targets while operating as a far larger incumbent.
• Novartis AG: Through its acquisition of Cynapsus/Sunovion and prior internal thin-film work, Novartis owns significant prescription sublingual film know-how — a direct comparable for the prescription soluble-film pathway NTFP is pursuing.

Others

• Pfizer Inc. Operates established soluble-film commercial products (e.g., Nurtec ODT-adjacent fast-dissolve technologies) and has historically partnered with thin-film developers; represents both a competitor for partner deals and a potential acquirer/partner.

Emerging players

• Aprecia Pharmaceuticals: Specialty pharma using an additive-manufacturing (3D-printing) platform to produce porous oral dosage forms. Comparable as a small platform pharma pursuing differentiated oral solid dosage forms, though manufacturing modality differs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/novathinfilm
• LinkedInlinkedin.com/in/nova-thin-film-0458a4224

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nova Thin Film Pharmaceuticals